問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Digestive System Department

Division of Hematology & Oncology

Division of Radiation Therapy

Division of Thoracic Medicine

Division of General Internal Medicine

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

更新時間：2023-11-06

陳三奇Chen, San-Chi
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

93Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳三奇

List

121Cases

2019-10-01 - 2022-03-02

Phase III

A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

  • Condition/Disease

    Advanced or Metastatic Biliary Tract Cancer

  • Test Drug

    NUC-1031 for injection (Acelarin®)

Participate Sites
5Sites

Recruiting5Sites

2021-05-03 - 2022-07-07

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-03-01 - 2021-01-04

Phase II

RATIONALE-208: A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma

  • Condition/Disease

    Previously Treated Unresectable Hepatocellular Carcinoma

  • Test Drug

    BGB-A317

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

侯明模
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2020-12-01 - 2023-12-31

Phase III

A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements-FOENIX-CCA3

  • Condition/Disease

    Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

  • Test Drug

    Futibatinib（TAS-120）

Participate Sites
6Sites

Recruiting6Sites

2021-09-01 - 2023-08-09

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-08-01 - 2022-08-31

Phase I/II

A Phase I/II, Open Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI 888 in Patients with Locally Advanced or Metastatic Solid Tumors.

  • Condition/Disease

    Metastatic Solid Tumors / Locally Advanced Solid Tumors

  • Test Drug

    OBI 888

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2018-05-30 - 2022-12-31

Phase II

An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    ATG-008

Participate Sites
6Sites

Recruiting5Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-06-30 - 2023-12-12

Phase III

A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Intermediate-stage Hepatocellular Carcinoma (HCC)

  • Test Drug

    Ipilimumab (5mg/mL; 40 ml)、 nivolumab (10mg/mL; 10 ml)

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2022-02-01 - 2022-04-06

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting1Sites

Terminated2Sites

2023-10-01 - 2030-12-31

Phase III

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Rilvegostomig

Participate Sites
8Sites

Recruiting8Sites

1 9 10 11 12 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB